Targovax secures $2.21 million Series A funding - MarketLine Financial Deals

Targovax secures $2.21 million Series A funding

Targovax secures $2.21 million Series A funding - MarketLine Financial Deals
Targovax secures $2.21 million Series A funding
Published Jan 25, 2012
3 pages — Published Jan 25, 2012
Price US$ 20.00  |  Buy this Report Now

About This Report

  
Abstract:

Targovax AS, a Norway-based oncology biopharma company, has secured NOK13 million ($2.21 million) in private capital.

  
Source:
Document ID
MA97011_120202
Country
Format:
PDF Adobe Acrobat
Buy Now

MarketLine Financial Deals—MarketLine Financial Deals – Identifying and tracking major financial activity across our full scope of company and sector coverage, MarketLine Financial Deals covers mergers & acquisitions, private equity/venture capital backed buyouts, investments, and exits, IPOs and secondary and follow on offerings, and private placements and exits. Additional non-corporate financial deals including partnership agreements, joint ventures, co-development and research, licensing and co-marketing agreements are also available.

About the Author


Cite this Report

  
MLA:
MarketLine Financial Deals. "Targovax secures $2.21 million Series A funding" Jan 25, 2012. Alacra Store. Dec 03, 2016. <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Targovax-secures-2-21-million-Series-A-funding-2052-76966>
  
APA:
MarketLine Financial Deals. (2012). Targovax secures $2.21 million Series A funding Jan 25, 2012. New York, NY: Alacra Store. Retrieved Dec 03, 2016 from <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/Targovax-secures-2-21-million-Series-A-funding-2052-76966>
  
US$ 20.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our MarketLine Financial Deals from one place.